Achillion Soars as FDA Says Hepatitis C Trial Can Resume

June 10, 2014 1:55 PM

14 0

Achillion Pharmaceuticals Inc. (ACHN:US), whose rival in hepatitis C made a $3.85 billion deal with Merck & Co. yesterday, soared (ACHN:US) to its highest price ever after U.S. regulators let it restart trials of a top pipeline product.

The Food and Drug Administration stopped study of sovaprevir last year over concerns the drug damages the liver. The treatment is in the second of three stages of testing usually required before approval.

Read more

To category page